DexCom, Inc.
DexCom, Inc. (DXCM) designs and sells continuous glucose monitoring (CGM) systems used by people with diabetes and healthcare providers. Its product suite—sensors, transmitters and supporting software—aims to provide real‑time glucose readings and trend data, with recurring revenue from consumable sensors and subscription services. Key positives include strong adoption in type 1 diabetes, a growing addressable market among type 2 patients, ongoing product upgrades (including smaller form factors) and partnerships with insulin‑delivery firms. Risks include competitive pressure (from established medical device makers and newer entrants), reimbursement and regulatory outcomes across markets, supply chain constraints and the potential for device recalls or pricing pressure. With a market capitalisation around $27.4bn, DexCom is often viewed as a growth‑oriented medical device company; investors should weigh revenue visibility from consumables against execution and regulatory risks. This is general information only, not personalised investment advice; returns are not guaranteed and share values can fall as well as rise.
Why It's Moving
DexCom Charts Cautious Path Into 2026 Despite Strong Q4 Results and Margin Expansion
- DexCom projects 2026 revenues of $5.16-$5.25 billion, representing 11-13% growth, with adjusted gross margins expanding to 63-64% and operating margins around 22-23%, driven by the newly launched G7 15-day system and growing Stelo adoption
- The company's cautiously optimistic 2026 outlook contrasts with Wall Street's higher expectations, sparking investor concern that growth may decelerate more sharply than anticipated despite strong clinical momentum in the CGM market
- Manufacturing issues continue to pressure near-term profitability, though DexCom expects scrap rates to normalize and the higher-margin G7 15-day product to deliver meaningful benefits, positioning the company for margin recovery if execution improves
DexCom Charts Cautious Path Into 2026 Despite Strong Q4 Results and Margin Expansion
- DexCom projects 2026 revenues of $5.16-$5.25 billion, representing 11-13% growth, with adjusted gross margins expanding to 63-64% and operating margins around 22-23%, driven by the newly launched G7 15-day system and growing Stelo adoption
- The company's cautiously optimistic 2026 outlook contrasts with Wall Street's higher expectations, sparking investor concern that growth may decelerate more sharply than anticipated despite strong clinical momentum in the CGM market
- Manufacturing issues continue to pressure near-term profitability, though DexCom expects scrap rates to normalize and the higher-margin G7 15-day product to deliver meaningful benefits, positioning the company for margin recovery if execution improves
When is the next earnings date for DexCom, Inc. (DXCM)?
DexCom's next earnings release is estimated between April 23-30, 2026, with most sources pointing to late April as the likely announcement window. The company has not yet officially confirmed the specific date, though the estimate is based on historical earnings release patterns. This earnings report will cover the company's first quarter of fiscal 2026 (Q1 2026). Investors should monitor DexCom's investor relations website for an official announcement of the confirmed earnings date and time.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying DexCom's stock as it has a target price of $86.89, indicating growth potential.
Financial Health
DexCom is successfully generating strong revenue and cash flow, reflecting its solid market position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring DXCM
At-Home Treatment Revolution | FDA Approval Impact
The FDA's approval of an injectable, at-home version of Eisai and Biogen's Alzheimer's drug signals a major shift in chronic disease management. This creates an investment opportunity in companies that develop advanced drug delivery systems and support at-home patient care.
Published: September 1, 2025
Explore BasketAt-Home Healthcare Stocks Explained | FDA Approval
The FDA's approval of an injectable, at-home version of Eisai and Biogen's Alzheimer's drug simplifies treatment and reduces the need for hospital visits. This development highlights a broader trend toward at-home care, creating potential investment opportunities in companies that provide related medical devices and healthcare services.
Published: August 30, 2025
Explore BasketWearable Tech IP Wars: What Investors Should Know
Masimo's lawsuit against U.S. Customs, following a reversal of an import ban on Apple Watches, highlights the fierce competition over intellectual property in wearable health. This theme focuses on the medical technology companies and competitors poised to benefit from the ongoing patent battles in the lucrative health-monitoring device market.
Published: August 21, 2025
Explore BasketPharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Published: August 19, 2025
Explore BasketDigital Therapeutics & Prescription Apps
Software is becoming the new medicine. These carefully selected companies are developing FDA-cleared applications that treat everything from mental health to diabetes. With growing insurance reimbursement and massive scalability, these digital treatments represent healthcare's next frontier.
Published: June 17, 2025
Explore BasketDigital Therapeutics
Software that works like medicine. These companies are creating clinically validated digital tools that treat and manage diseases just like traditional pharmaceuticals, but with the scalability of technology. Professional investors see enormous potential in this rapidly evolving healthcare frontier.
Published: June 17, 2025
Explore BasketBio-Hacking Portfolio
Discover companies at the cutting edge of human optimization, where biology meets technology. These carefully selected stocks represent innovators developing data-driven solutions for personalized health, enhanced performance, and extended longevity.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Recurring revenue growth
Consumable sensors and subscription services support revenue predictability, though sales can fluctuate with reimbursement and competitive dynamics.
Product innovation pipeline
Smaller sensors, improved accuracy and system integrations keep the product roadmap active, but technical or regulatory setbacks can affect adoption.
Global expansion potential
International markets present sizeable opportunity as CGM adoption rises, balanced by differing regulatory regimes and payer systems that can slow rollout.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Abbott Laboratories
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
Agilent Technologies Inc.
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
Align Technology Inc.
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
